SeaStar Medical (ICU) Projected to Announce Quarterly Earnings on Wednesday

SeaStar Medical (NASDAQ:ICU) will likely be releasing its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect SeaStar Medical to announce earnings of ($0.97) per share and revenue of $0.4860 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

SeaStar Medical (NASDAQ:ICU) last issued its earnings results on Wednesday, May 13th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08). The company had revenue of $0.49 million during the quarter, compared to the consensus estimate of $0.44 million. SeaStar Medical had a negative return on equity of 146.29% and a negative net margin of 828.62%. On average, analysts expect SeaStar Medical to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

SeaStar Medical Stock Performance

Shares of NASDAQ:ICU opened at $3.19 on Wednesday. The firm has a market cap of $12.76 million, a PE ratio of -0.66 and a beta of -1.05. The firm’s 50 day simple moving average is $3.68 and its 200-day simple moving average is $3.37. SeaStar Medical has a one year low of $2.07 and a one year high of $12.50.

Institutional Investors Weigh In On SeaStar Medical

A number of institutional investors have recently added to or reduced their stakes in ICU. Millennium Management LLC purchased a new position in SeaStar Medical in the third quarter valued at about $102,000. Jane Street Group LLC purchased a new position in shares of SeaStar Medical in the 4th quarter worth approximately $30,000. Finally, XTX Topco Ltd raised its stake in shares of SeaStar Medical by 395.4% during the 2nd quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after acquiring an additional 48,674 shares in the last quarter. Institutional investors own 1.69% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Wall Street Zen downgraded SeaStar Medical from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Maxim Group set a $8.00 target price on SeaStar Medical and gave the stock a “buy” rating in a report on Thursday, May 14th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of SeaStar Medical in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, SeaStar Medical presently has an average rating of “Hold” and a consensus price target of $8.00.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.